Abstract
Importance By age 40 years over 90% of adults with Down syndrome (DS) have Alzheimer’s disease (AD) pathology and most progress to dementia. Despite having few systemic vascular risk factors, individuals with DS have elevated cerebrovascular disease (CVD) markers that track with the clinical progression of AD, suggesting a role for CVD that is hypothesized to be mediated by inflammatory factors.
Objective To examine the pathways through which small vessel CVD contributes to AD-related pathophysiology and neurodegeneration in adults with DS.
Design Cross sectional analysis of neuroimaging, plasma, and clinical data.
Setting Participants were enrolled in Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS), a multisite study of AD in adults with DS.
Participants One hundred eighty-five participants (mean [SD] age=45.2 [9.3] years) with available MRI and plasma biomarker data were included. White matter hyperintensity (WMH) volumes were derived from T2-weighted FLAIR MRI scans and plasma biomarker concentrations of amyloid beta (Aβ42/Aβ40), phosphorylated tau (p-tau217), astrocytosis (glial fibrillary acidic protein, GFAP), and neurodegeneration (neurofilament light chain, NfL) were measured with ultrasensitive immunoassays.
Main Outcomes and Measures We examined the bivariate relationships of WMH, Aβ42/Aβ40, p-tau217, and GFAP with age-residualized NfL across AD diagnostic groups. A series of mediation and path analyses examined causal pathways linking WMH and AD pathophysiology to promote neurodegeneration in the total sample and groups stratified by clinical diagnosis.
Results There was a direct and indirect bidirectional effect through GFAP of WMH on p-tau217 concentration, which was associated with NfL concentration in the entire sample. Among cognitively stable participants, WMH was directly and indirectly, through GFAP, associated with p-tau217 concentration, and in those with MCI, there was a direct effect of WMH on p-tau217 and NfL concentrations. There were no associations of WMH with biomarker concentrations among those diagnosed with dementia.
Conclusions and Relevance The findings suggest that among individuals with DS, CVD promotes neurodegeneration by increasing astrocytosis and tau pathophysiology in the presymptomatic phases of AD. This work joins an emerging literature that implicates CVD and its interface with neuroinflammation as a core pathological feature of AD in adults with DS.
Question Do white matter hyperintensities, a magnetic resonance imaging marker of small vessel cerebrovascular disease, predict plasma Alzheimer’s biomarker concentrations of amyloid, tau, and neuroinflammatory pathophysiology and downstream neurodegeneration in adults with Down syndrome?
Findings Increases in white matter hyperintensity volume precede and promote inflammation- and tau-related pathophysiology, directly and indirectly, leading to downstream neurodegeneration.
Meaning Small vessel cerebrovascular disease may contribute to the pathophysiological progression of Alzheimer’s disease in adults with Down syndrome. These findings support the hypothesis that cerebrovascular disease is a core feature of Alzheimer’s disease in adults with Down syndrome.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: NCE, PJL, MJA, BR, MEP, SO, LFA, MM, DLT, BLH, BTC, JHL, FL, HDR, SZ, ITL, MAY, JG, DMW, EH, and AMB had financial support from National Institute on Aging for the submitted work; OH has received consulting fees for AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens; SZ has received consulting fees from Lundbeck; DMW has received consulting fees from Biohaven Therapeutics; EH has received consulting fees for Alzheon and Cyclo Therapeutics; AMB has received consulting fees from Cogstate, Cognito Therapeutics, and Cognition Therapeutics.
Funding Statement
This work was supported by US National Institutes of Health grants RF1 AG079519, U19 AG068054, U01 AG051412, and U01 AG051406.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review boards of Columbia University, Massachusetts General Hospital, University of California, Irvine, University of Pittsburgh, University of Wisconsin, Madison, and Cambridge University, and written informed consent was obtained from the participants and/or their legal guardian or legally authorized representative.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# A complete listing of the Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS) investigators can be found at the conclusion of this manuscript
Author list initials and abstract formatting. No components of the manuscript file have been changed.
Data Availability
Qualified investigators can submit requests for access to data and samples (https://pitt.co1.qualtrics.com/jfe/form/SV_cu0pNCZZlrdSxUN), and all requests will be reviewed by ABC-DS investigators and NIH staff.
